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PEOPLE RECRUITMENT AND SAMPLE COLLECTION (9 MONTHS)
200 HIV+ ART, <20 copies/ml
❖65 HAND
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RNA quantification
NanoDrop and Qubit 
fluorometer
SEQUENCING (3 MONTHS)2
‣ NEB-based directional RNA-Seq (Illumina)
‣ RT-PCR amplification cDNA 
library
‣ HigSeq2000 Illumina sequencer
‣ Bowtie software (FastQ format)
DATA ANALYSIS (3 MONTHS)3
Monocyte and CSF RNA-seq data
• Spliced Transcripts Alignment 
to Reference (STAR, Illumina)
• Trim Galore software
• Normalitzation of raw data
• Bioconductor software package
• p<0,05




VALIDATION OF RNA-SEQ DATA (3 MONTHS)4
❖Library generation
❖Next generation sequencing
qPCR of significant results found in RNA-seq
SCID MICE ORDER (3 MONTHS)1
Ethics Committe approval
16/20 HIV+ (HAND 
model) SCID mice





Intracerebral injections of 
HIV-1 monocyte-derived 
macrophages in 16 mice
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End of treatment
Treatment monitoring with panel of 
HAND biomarkers










Total RNA kit (Miltenyi 
Biotec) for monocytes

















Diagnosis of HAND 
(IHDS test)
HAND questionnaire 
(AAN and HNRC criteria)
ANALYSIS OF BIOMARKERS (3 MONTHS)2
STATISTICAL ANALYSIS (3 MONTHS)2
T student test
Wilcoxon rank sum test
Turkey test
p<0,05
M A T E R I A L S  A N D  M E T H O D S
B A C K G R O U N D
To  find  biomarkers  associated  with 
neurodegeneration  in  HIV-1  infected 
individuals
1
To  find  a  transcriptomic  profile 
associated with neurodegeneration in 
HIV-1 infected individuals
To  test  the  panel  of  HAND 
biomarkers in mice treated with anti-
inflammatory  drugs  administered 
intranasally
HIV  associated  neurocognitive  disorder  (HAND)  has  become  a  common 
comorbidity in more than 30% patients infected by human immunodeficiency 
virus (HIV)-1, despite the presence of different antiretroviral treatments (ART).
HAND is associated with neuroinflammation and several biomarkers have been 
described  throughout  the  last  years  to  diagnose  HAND,  but  a  complete 
diagnostic analysis has not been found yet.
There  are  several  clinical  HAND 
syndromes depending on the severity 
of neurodegeneration: HIV associated 
dementia (HAD), mild neurocognitive 
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Furthermore,  these  biomarkers 
can be used to monitor treatments 
as  nasal  administration  of  anti-
inflammatory  drugs  to  improve 
symptoms of HAND.
H Y P O T E S I S
The levels of molecules present in 
blood  and  cerebrospinal  fluid 
(CSF)  are  associated  to  chronic 
inflammation.  They  can  be  used 
as  biomarkers  to  predict 
neurodegeneration  in  HIV-1 
infected  individuals  in  order  to 
treat the patients earlier.
O B J E C T I V E S
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E X P E C T E D  R E S U L T S D I F F U S I O N  P L A N
Some of the molecules analysed may be used as HAND biomarkers, considering that they 
are significantly more expressed in HIV+ individuals with HAND than in patients with no 
neurodegeneration.
There may be some CSF and monocytes RNAs in HIV+ patients with HAND symptoms 
differentially expressed in comparison to HIV+ patients without these symptoms.
The panel of biomarkers may be used to monitor drug treatments in mice.  Furthermore, 
BB-882 and BB-1101 anti-inflammatory treatments provided through intranasal route may 




❖ 3 or more publications in high-impact journals of this area
❖ Results presentation at some relevant conferences, e.g. the 
Conference on Retroviruses and Opportunistic Infections 
(CROI)
❖ Dissemination of results to patients
❖ Dissemination of results to HIV seminars
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OBJECTIVE 2 OBJECTIVE 3OBJECTIVE 1
Figure  1.  Percentage  of  the  different  HAND 
clinical syndromes before and after ART
Figure 2. Blood and CSF extraction and collection
Figure 3. Study design and number of times that biomarkers 
will be analysed
Proposal of research project
Study of Biomarkers in HIV-1 Infected Individuals with 
Neurocognitive Disorders (HAND)
